Lipiodol ultra-fluid: an antitumor agent-in vitro study

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Lipiodol Ultra-Fluid (LUF) is a contrast agent used in hepatocellular carcinoma (HCC) diagnosis and treatment via hepatic intra-arterial infusion.
• Hepatoma cells actively uptake and retain LUF, indicating therapeutic potential for targeted drug delivery.
• An intratumoral diffuser concept was proposed based on LUF's characteristics.

Purpose of the Study:

• To investigate the in vitro effects of LUF on various cell types before in vivo studies.
• To elucidate and refine lipiodol-based chemotherapy strategies.
• To assess the antiproliferative and cytotoxic activities of LUF on different cell lines.

Main Methods:

• In vitro assessment of LUF effects on HepG2 (hepatoma), MCF-7 (breast cancer), murine macrophages, and human hepatocytes.
• Evaluation of cell viability using Trypan blue exclusion assay.
• Measurement of extracellular lactate dehydrogenase (LDH) levels to assess cytotoxicity.

Main Results:

• LUF exhibited dose- and time-dependent antiproliferative and cytotoxic effects.
• Cytotoxicity varied significantly among cell types, being higher in cancerous cells and macrophages compared to human hepatocytes.
• Selective uptake and retention of LUF by cells led to increased lipoperoxidation and necrosis.

Conclusions:

• LUF acts as an in vitro antiproliferative and cytotoxic agent.
• Active uptake and selective retention of LUF contribute to cancer cell death through necrosis.
• LUF shows promise for targeted chemotherapy in hepatocellular carcinoma treatment.